Promises and Complications of Doxy-PEP for the Prevention of Sexually Transmitted Infections in People With HIV: Complex Cases

Assessment of Needs

Doxycycline postexposure prophylaxis (doxy-PEP) has emerged as a promising strategy to reduce the incidence of bacterial sexually transmitted infections (STIs) among people with HIV. As uptake increases, clinicians are increasingly encountering complex and challenging clinical scenarios that extend beyond standard guidance. This webinar will review the current evidence base and clinical recommendations for doxy-PEP use, with a particular focus on management considerations in complex cases that are not fully addressed by existing guidelines, including concerns related to antimicrobial resistance, use among persons assigned female at birth, and evolving data on dosing strategies. Participants will gain practical, case-based insights to support informed clinical decision-making, while also considering broader implications related to antimicrobial resistance.

Learning Objectives

On completion of this activity, learners will be able to:

• Describe evidence-based approaches to managing complex doxy-PEP cases that are not fully addressed by current guidelines
• Describe population-specific considerations for doxy-PEP use, including emerging data in persons assigned female at birth
• Describe current and emerging dosing strategies for doxy-PEP
• Describe the potential implications of widespread doxy-PEP use on antimicrobial resistance

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, April 28, 2026, 11:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Zucker reported no relevant financial relationships with ineligible companies. (Updated February 5, 2026)

Moderator

Dr Chew reported no relevant financial relationships with ineligible companies. (Updated January 26, 2026)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated January 26, 2026)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated January 26, 2026)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/